



Half Year Report 2018

Letter to Shareholders

Dear Shareholders

The first half of 2018 was marked by the outstanding financial performance the Company generated, achieving record revenues and profitability relative to recent years. The results further underscore the Company's position as a telehealth leader in its respective markets.

In addition to the positive core operating performance during this period, the Company generated an income of USD 8.9m from cost savings delivered under Chronic Disease Management Services contracts in Germany, relating to the year 2015-2017. These results demonstrate the effectiveness of our Chronic Disease Management programs and the value they deliver to our customers and the patients monitored on the platform.

Revenues during the period were USD 29.0m (including income of USD 8.9m as mentioned above), up from USD 18.3m in previous half year's revenues. EBITDA was USD 12.9m, compared to an EBITDA of USD 5.8m in the first half-year of 2017. The first half of 2018 resulted in a net income of USD 8.7m versus a net income of USD 2.0m in the first half of 2017.

In Germany, revenues grew to by 127% to USD 18.4m resulting from the additional income of USD 8.9m and growth in overall telehealth patients compared to USD 9.1 in constant currency in the

previous half year. In Israel, revenues were USD 10.5m and similar to last year, in constant currency.

The Company continues to explore ways to enrich the breadth of its portfolio of services with new technologies and further customer offerings.

Issues pertaining to the mandatory tender offer continued to unfold during the year with the Swiss Takeover Board ("Takeover Board"), following the grant of 2 extensions, issuing a decision on September 1 2018, declaring that that the for all listed shares of the Company by Himalaya (Cayman Islands) TMT Fund, Himalaya Asset Management Ltd, Xiang Xu, Kun Shen and Mengke Cai was not submitted in due time and as a result that all voting rights and related rights of the parties are suspended with immediate effect until the publication of a mandatory offer approved by the Takeover Board and on the opening of an administrative criminal proceedings pursuant to Art. 152 FinfraG 7.

On behalf of the Board of Directors and the management team, we thank all employees for their hard work and our business partners and shareholders for the trust they have placed in SHL

Sincerely,


Xuewen Wu

Chairman of the Board


Yoav Rubinstein
CEO



SHL Telemedicine Ltd.
1 January - 30 June

Half-Year Report 2018

3

INDEX

5		Auditors' review report to the shareholders and board of directors
6		Consolidated Balance Sheets
8		Consolidated Statements of Comprehensive Income
9		Consolidated Statements of Changes in Equity
10		Consolidated Statements of Cash Flows
12		Notes to Consolidated Financial Statements

The Shareholders and Board of Directors SHL Telemedicine Ltd.

Auditors' review report to the shareholders and board of directors of SHL Telemedicine Ltd.

Introduction

We have reviewed the accompanying interim condensed consolidated financial statements of SHL Telemedicine Ltd. ("the Company") and its subsidiaries as of June 30, 2018, which comprise the interim consolidated balance sheet as of June 30, 2018, and the related interim consolidated statements of comprehensive income, changes in equity and cash flows for the six month period then ended and explanatory notes. Management is responsible for the preparation and presentation of this interim financial information in accordance with International Accounting Standard 34, "Interim Financial Reporting" ("IAS 34"). Our responsibility is to express a conclusion on this interim financial information based on our review.

Scope of review

We conducted our review in accordance with International Standard on Review Engagements 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity". A review of interim financial information consists of making inquiries, primarily of persons responsible for financial

and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the accompanying interim condensed consolidated financial statements are not prepared, in all material respects, in accordance with IAS 34.

Tel-Aviv, Israel

September 17, 2018

Kost Forer Gabbay and Kasierer

KOST FORER GABBAY & KASIERER

A Member of Ernst & Young Global

CONSOLIDATED BALANCE SHEETS U.S. dollars in thousands

	June 30,		December 31,
	2018	2017	2017
	Unaudited		Audited
ASSETS			
CURRENT ASSETS:			
Cash and cash equivalents	3,950	16,632	5,683
Short-term investments	4,590	3,509	4,711
Trade receivables	14,925	4,236	5,751
Prepaid expenses	749	763	756
Inventory	1,859	2,501	2,208
Other accounts receivable	7,548	1,493	8,697
	33,621	29,134	27,806
NON-CURRENT ASSETS:			
Prepaid expenses	2,530	2,698	2,652
Long-term deposits	845	884	884
Deferred taxes	2,753	2,362	2,880
	6,128	5,944	6,416
PROPERTY AND EQUIPMENT, NET	3,860	5,483	4,946
GOODWILL	16,217	16,738	16,998
INTANGIBLE ASSETS, NET	8,089	10,053	9,337
Total assets	67,915	67,352	65,503


The accompanying notes are an integral part of the interim consolidated financial statements.

CONSOLIDATED BALANCE SHEETS U.S. dollars in thousands

	June 30,		December 31,
	2018	2017	2017
	Unaudited		Audited
LIABILITIES AND EQUITY			
CURRENT LIABILITIES:			
Credit from banks and current maturities	11,559	14,603	12,920
Deferred revenues	2,055	1,462	1,469
Income taxes payable	1,678	2,663	1,588
Trade payables	1,085	1,485	958
Other accounts payable	12,718	8,402	15,989
	29,095	28,615	32,924
NON-CURRENT LIABILITIES:			
Long-term loans	205	8,711	1,486
Deferred revenues	231	251	369
Income taxes payable	-	228	-
Deferred taxes	591	786	685
Employee benefit liabilities	843	954	830
	1,870	10,930	3,370
Total liabilities	30,965	39,545	36,294
EQUITY:			
Issued capital	31	31	31
Additional paid-in capital	96,284	95,728	95,951
Treasury shares	(2,392)	(2,429)	(2,429)
Foreign currency translation reserve	(1,767)	(1,140)	(403)
Capital reservs	558	496	561
Accumulated deficit	(55,764)	(64,879)	(64,502)
Total equity	36,950	27,807	29,209
Total liabilities and equity	67,915	67,352	65,503

The accompanying notes are an integral part of the interim consolidated financial statements.

September 17, 2018
Date of approval of the
financial statements


Xuewen Wu
Chairman of the Board


Yoav Rubinstein
CEO

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

U.S. dollars in thousands (except per share amounts)

	Six months ended June 30,		Year ended
	2018	2017	December 31,
	Unaudited		Audited
Revenues	20,139	17,921	36,964
Change in revenues estimate	8,878	397	414
Total revenues	29,017	18,318	37,378
Cost of revenues	9,916	8,947	17,785
Gross profit	19,101	9,371	19,593
Research and development costs	1,416	1,490	3,015
Selling and marketing expenses	3,730	3,611	7,329
General and administrative expenses	3,644	4,167	7,966
Other expenses	-	-	549
Other income	-	(3,308)	(3,366)
Operating profit	10,311	3,411	4,100
Financial income	161	371	469
Financial expenses	(483)	(832)	(1,555)
Profit before taxes on income	9,989	2,950	3,014
Taxes on income	1,254	919	606
Net profit	8,735	2,031	2,408
Other comprehensive income:			
Other comprehensive income not to be reclassified to profit or loss in subsequent periods:			
Remeasurement gains on defined benefit plans	-	-	88
	-	-	88
Other comprehensive income to be reclassified to profit or loss in subsequent periods:			
Transfer to the profit or loss in respect of available-for-sale investments	-	(222)	(268)
Gain on available-for-sale investments	-	13	36
Foreign currency translation reserve	(1,364)	2,301	3,038
	(1,364)	2,092	2,806
Total other comprehensive income	(1,364)	2,092	2,894
Total comprehensive income	7,371	4,123	5,302
Earnings per share:			
Basic and diluted earnings	0.83	0.19	0.23

The accompanying notes are an integral part of the interim consolidated financial statements.

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY

U.S. dollars in thousands

	Issued capital	Additional paid-in capital	Treasury shares	Foreign currency translation reserve	Capital reservs*	Accumulated deficit	Total
Balance as of January 1, 2017 (audited)	31	95,859	(2,429)	(3,441)	705	(66,910)	23,815
Share-based payments	-	92	-	-	-	-	92
Net profit	-	-	-	-	-	2,408	2,408
Total other comprehensive income	-	-	-	3,038	(144)	-	2,894
Balance as of December 31, 2017 (audited)	31	95,951	(2,429)	(403)	561	(64,502)	29,209
Cummulative effect of initial adoption of IFRS 9 (see Note 2a)	-	-	-	-	(3)	3	-
Balance as of January 1, 2018 (after initial adoption of IFRS9)	31	95,951	(2,429)	(403)	558	(64,499)	29,209
Share-based payments	-	370	-	-	-	-	370
Exercise of options	-	(37)	37	-	-	-	-
Net profit	-	-	-	-	-	8,735	8,735
Total other comprehensive income	-	-	-	(1,364)	-	-	(1,364)
Balance as of June 30, 2018 (unaudited)	31	96,284	(2,392)	(1,767)	558	(55,764)	36,950

* As of June 30, 2018, the balance is comprised of cumulative gains on defined benefit plans. As of December 31, 2017, the balance is comprised of cumulative gains on defined benefit plans in the amounts of \$ 558 and reserve for available -for-sale investments in the amount of \$3.

	Issued capital	Additional paid-in capital	Treasury shares	Foreign currency translation reserve	Capital reservs*	Accumulated deficit	Total
Balance as of January 1, 2017 (audited)	31	95,859	(2,429)	(3,441)	705	(66,910)	23,815
Share-based payments	-	(131)	-	-	-	-	(131)
Net profit	-	-	-	-	-	2,031	2,031
Total other comprehensive income (loss)	-	-	-	2,301	(209)	-	2,092
Balance as of June 30, 2017 (unaudited)	31	95,728	(2,429)	(1,140)	496	(64,879)	27,807

* As of June 30, 2017, the capital reserve for available for sale investments amounts to \$ 25 and the cumulative gains on defined benefit plans amounts to \$ 471.

The accompanying notes are an integral part of the interim consolidated financial statements.

CONSOLIDATED STATEMENTS OF CASH FLOWS

U.S. dollars in thousands

	Six months ended		Year ended
	June 30,		December 31,
	2018	2017	2017
	Unaudited		Audited
Cash flows from operating activities:			
Net profit	8,735	2,031	2,408
Adjustments required to reconcile net income to net cash provided by operating activities :			
Income and expenses not involving operating cash flows:			
Depreciation and amortization	2,572	2,388	4,519
Capital loss (gain) from sale of property and equipment	39	(6)	3
Impairment of property, plant and equipment	-	-	117
Impairment of intangible assets	-	-	350
Change in employee benefit liabilities, net	52	(21)	(53)
Financial expenses, net	214	461	889
Cost of share-based payments	370	(131)	92
Other capital loss	29	-	-
Taxes on income	1,254	919	606
	4,530	3,610	6,523
Changes in operating assets and liabilities:			
Decrease (increase) in trade receivables, net	(9,931)	6,344	5,055
Decrease in inventory	263	130	431
Decrease (increase) in prepaid expenses	(45)	189	270
Decrease (increase) in other accounts receivable	967	28	(6,908)
Increase (decrease) in trade payables	173	146	(296)
Increase (decrease) in deferred revenues	527	(371)	(330)
Increase (decrease) in other accounts payable	(2,078)	1,158	7,724
	(10,124)	7,624	5,946
Cash paid and received:			
Interest received	58	3	137
Interest paid	(227)	(400)	(972)
Income taxes received	-	153	179
Income taxes paid	(1,696)	(1,099)	(2,377)
	(1,865)	(1,343)	(3,033)
Net cash provided by operating activities	1,276	11,922	11,844

The accompanying notes are an integral part of the interim consolidated financial statements.

CONSOLIDATED STATEMENTS OF CASH FLOWS

U.S. dollars in thousands

	Six months ended		Year ended
	June 30,		December 31,
	2018	2017	2017
	Unaudited		Audited
Cash flows from investing activities:			
Purchase of property and equipment	(372)	(152)	(489)
Investment in intangible assets	(353)	(216)	(1,113)
Proceeds from sale of property and equipment	-	9	9
Purchase of short-term investments	(673)	(612)	(2,492)
Proceeds from sale of short-term investments	557	1,863	2,602
Net cash provided by (used in) investing activities	(841)	892	(1,483)
Cash flows from financing activities:			
Payment of long-term loans	(2,034)	(2,351)	(11,265)
Net cash used in financing activities	(2,034)	(2,351)	(11,265)
Effect of exchange rate changes on cash and cash equivalents	(134)	280	698
Increase (decrease) in cash and cash equivalents	(1,733)	10,743	(206)
Cash and cash equivalents at the beginning of the period	5,683	5,889	5,889
Cash and cash equivalents at the end of the period	3,950	16,632	5,683

The accompanying notes are an integral part of the interim consolidated financial statements.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands

NOTE 1 | GENERAL

- a. These consolidated financial statements have been prepared in a condensed format as of June 30, 2018 and for the six months then ended. These condensed consolidated financial statements should be read in conjunction with the annual consolidated financial statements and accompanying notes of SHL Telemedicine Ltd. (“the Company”) as of December 31, 2017 and for the year then ended (“the annual financial statements”).
- b. Following are data regarding the Israeli CPI and the exchange rates of the Euro, U.S. dollar and the Swiss Franc in relation to the new Israeli Shekel (NIS):

For the period ended	Israeli	Exchange rate		
	CPI Points*	€ 1	U.S. \$ 1	CHF 1
			NIS	
June 30, 2018	223.6	4.25	3.65	3.67
June 30, 2017	220.7	3.99	3.49	3.65
December 31, 2017	221.6	4.15	3.46	3.55
Change during the period	%	%	%	%
June 2018 (6 months)	0.1	2.4	5.4	3.3
June 2017 (6 months)	0.2	(1.4)	(9)	(3.2)
December 2017 (12 months)	0.4	2.7	(9.8)	(5.6)

* The index on an average basis of 1993 = 100.

NOTE 2 | SIGNIFICANT ACCOUNTING POLICIES

a. Basis of preparation of the interim condensed consolidated financial statements:

The interim condensed consolidated financial statements for the six months ended June 30, 2018 have been prepared in accordance with generally accepted accounting principles for the preparation of financial statements for interim periods, as prescribed in IAS 34, “Interim Financial Reporting.”

The significant accounting policies and methods of computation adopted in the preparation of the interim condensed consolidated financial statements are consistent with those followed in the preparation of the annual financial statements, except as described below.

Revenues:

In May 2014, the IASB issued IFRS 15, “Revenue from Contracts with Customers” (“IFRS 15”). IFRS 15 replaces all current revenue recognition requirements under IAS 18. Under IFRS 15 revenue is recognized at an amount that reflects the consideration to which entity expects to be entitled in exchange for transferring goods or services to a customer.

The adoption of IFRS 15 did not have a material effect on the consolidated financial statements.

Financial Instruments

In July 2014, the IASB issued the final and complete version of IFRS 9, “Financial Instruments” (“IFRS 9”), which replaces IAS 39, “Financial Instruments: Recognition and Measurement”. IFRS 9 mainly focuses on the classification and measurement of financial assets and it applies to all assets in the scope of IAS 39. IFRS 9 also prescribes new hedge accounting requirements.

The Company has elected to apply IFRS 9 retroactively without restatement of comparative data. As of December 31, 2017, short-term investments included certain investments in securities that were classified as available-for-sale, for which unrealized gains and losses on these investments were recorded in other comprehensive income. Under IFRS 9, the Company has elected to measure these investments at fair value through profit or loss.

The adoption of IFRS 9 resulted in a reclassification in equity of \$3 from capital reserves to accumulated deficit as of January 1, 2018.

b. Disclosure of new IFRSs in the period prior to their adoption.

IFRS 16, “Leases”

In January 2016, the IASB issued IFRS 16, “Leases” (“IFRS 16”). According to IFRS 16, a lease is a contract, or part of a contract, that conveys the right to use an asset for a period of time in exchange for consideration.

The Company is evaluating the possible effects of IFRS 16 but is presently unable to quantify the impact on the financial statements.

NOTE 3 | REVENUES

	Six months ended June 30,		Year ended December 31,
	2018	2017	2017
	Unaudited		Audited
Revenues for services performed during the period	19,515	17,505	36,037
Revenues from sale of devices	624	416	927
Change in revenues estimate ¹	8,878	397	414
Total	29,017	18,318	37,378

¹ Due to the significant variability of the various factors that can affect the level of cost savings and the resulting difficulty in measuring such cost savings reliably, the Company recognizes revenues from performance-based contracts only after receiving final data as to the actual cost savings. In the six months period ended June 30, 2018, the Company recognized revenue in respect of cost savings arising from the years 2015, 2016 and 2017.

NOTE 4 | MATERIAL EVENTS DURING THE REPORTING PERIOD

During the period, the Board of Directors approved the grant of 391,136 options to the Company’s CEO, under the 2015 Executive and Key Employee Israeli Share Option Plan. The options shall vest over a period of 3 years from the date of his appointment as CEO in 2017 (25% on June 1, 2018, and 9.375% each quarter thereafter). The weighted average

fair value of options granted is CHF 1.293-1.612 (\$ 1.332-1.616). The weighted average fair value was estimated based on the binomial model using the following data and assumptions: share price - CHF 6.31-7.50; exercise price - CHF 6.85-7.70; expected volatility - 37.91% -40.42%; risk free interest rate - 2.24%; expected dividend -0%; and expected average life of options - 2.81-3.15 years.

NOTE 5 | SEGMENT INFORMATION

As presented in the annual financial statements, the Group operates in three geographic segments: Israel, Europe (principally Germany) and Rest of world. Revenues are allocated based on the location of the end customer. The Group presents disaggregated revenue information based on types of customers: Individual customers and communities, Institutions and payers (income from service agreements with institutions, insurance companies and HMOs), and others.

a. Segment revenues:

	Individuals and communities	Institutions and payers	Others	Total
Six months ended June 30, 2018 (unaudited):				
Europe	-	18,394	-	18,394
Israel	9,954	594	-	10,548
Others	-	-	75	75
Total				
revenues	9,954	18,988	75	29,017

	Individuals and communities	Institutions and payers	Others	Total
Six months ended June 30, 2017 (unaudited):				
Europe	-	8,097	-	8,097
Israel	9,462	580	-	10,042
Others	-	-	179	179
Total				
revenues	9,462	8,677	179	18,318

	Individuals and communities	Institutions and payers	Others	Total
Year ended December 31, 2017 (audited):				
Europe	-	16,634	-	16,634
Israel	19,164	1,313	-	20,477
Others	-	-	267	267
Total				
revenues	19,164	17,947	267	37,378

b. Segment profit (loss):

	Six months ended June 30,		Year ended December 31,
	2018	2017	2017
	Unaudited		Audited
Europe	9,946	169	576
Israel	2,064	2,170	4,494
Others	(347)	(510)	(1,069)
	11,663	1,829	4,001

Unallocated income and expenses:

Corporate and R&D expenses	(1,352)	(1,726)	(3,267)
Other income	-	3,308	3,366
Operating profit	10,311	3,411	4,100
Financial expenses, net	(322)	(461)	(1,086)
Profit before taxes on income	9,989	2,950	3,014

NOTE 6 | SUBSEQUENT EVENTS

- a. Following Note 25b to the annual financial statements, on June 27, 2018, the Swiss Takeover Board has taken the following decision regarding a request for extension of the deadline to make a mandatory tender offer by Himalaya (Cayman Islands) TMT Fund, Himalaya Asset Management Ltd., Xiang Xu, Kun Shen, and Mengke Cai with respect to SHL:
1. The deadline for Himalaya (Cayman Islands) TMT Fund, Himalaya Asset Management Ltd., Xiang Xu, Kun Shen, and Mengke Cai to make a tender offer to the shareholders of SHL Telemedicine Ltd. is extended until 31 August 2018.
 2. This deadline extension is provided under the condition that Himalaya (Cayman Islands) TMT Fund, Himalaya Asset Management Ltd., Xiang Xu, Kun Shen and Mengke Cai inform the Takeover Board about the progress regarding the realization and the financing of the mandatory tender offer once a week.
 3. The main motion of Himalaya (Cayman Islands) TMT Fund, Himalaya Asset Management Ltd., Xian Xu, Kun Shen, and the motion para. 1 of Mengke Cai [motions to extend the deadline until 30 September 2018] are rejected.
 4. The main motion para. 1 [to reject the deadline extension request] as well as the motions para. 2-4 [to suspend voting rights of mandatory bidders; to forbid SHL and its organs to allow the exercise of the voting rights and related rights; to pay default interest of 5% p.a. on the offering price since 12 July 2017] of Nehama & Yoram Alroy Investment Ltd. and Elon Shalev are rejected.
 5. SHL Telemedicine Ltd. is obliged to inform the public on the deadline extension granted with this decision and to publish the orders of this decision. The publication has to be made at the same time as the publication of this decision by the Takeover Board.
 6. This decision will be published on the website of the Takeover Board after the notification of the parties.
 7. The fee jointly and severally charged to Himalaya (Cayman Islands) TMT Fund, Himalaya Asset Management Ltd., Xiang Xu, Kun Shen, and Mengke Cai amounts to CHF 20 thousands.
- b. On September 1, 2018, the Swiss Takeover Board (TOB) has taken the following decision 672/04 regarding a request for extension of the deadline to make a mandatory tender offer by Himalaya (Cayman Islands) TMT Fund, Himalaya Asset Management Ltd., Xiang Xu, Kun Shen, and Mengke Cai with respect to SHL as well as regarding a request of Nehama and Yoram Alroy Investment Ltd. and Elon Shalev to suspend the voting rights of the mandatory bidders:
1. The deadline for making a mandatory public offer by Himalaya (Cayman Islands) TMT Fund, Himalaya Asset Management Ltd., Xiang Xu, Kun Shen and Mengke Cai, to the shareholders of SHL Telemedicine Ltd. is not extended.
 2. The TOB declares that the mandatory public offer of Himalaya (Cayman Islands) TMT Fund, Himalaya Asset Management Ltd., Xiang Xu, Kun Shen and Mengke Cai to the shareholders of SHL Telemedicine Ltd. was not submitted in due time.
 3. All voting rights and related rights of Himalaya (Cayman Islands) TMT Fund, Himalaya Asset Management Ltd., Xiang Xu, Kun Shen and Mengke Cai for the shares in SHL Telemedicine Ltd. are suspended with immediate effect until the publication of a mandatory offer approved by the Takeover Board.
 4. The suspensive effect of any appeal against the present decision is withdrawn.
 5. All other requests are rejected.
 6. After the present notice has become legally effective, a notification will be sent to the Federal Department of Finance EFD on the opening of administrative criminal proceedings pursuant to Art. 152 FinfraG.
 7. SHL Telemedicine Ltd. is obliged to make this decision public by 3 September 2018 at the Latest.
 8. Following its publication by SHL Telemedicine in accordance with no. 7 above, this notice will be published on the website of the TOB.

9. The fee charged to Himalaya (Cayman Islands) TMT Fund, Himalaya Asset Management Ltd, Xiang Xu, Kun Shen and Mengke Cai, under joint and several liability, amounts to CHF 40 thousands.
- c. On September 3, 2018, Nehama and Yoram Alroy Investment Ltd., which is part of a group of shareholders of SHL, submitted a request to the board of directors of SHL to add some items to the agenda of the upcoming Special General Meeting (scheduled for October 18, 2018), amongst which: (1) the termination of office of the following board members: Mr. Wu, Mr. Su, Mr. He, Ms. Qian, Dr. Lo, and Ms. Shechter; and (2) the election of the following candidates as board members: Mr. Elon Shalev, Mr. Erez Alroy, Mr. Yariv Alroy and Mr. Erez Nachtomy.
- d. On September 6, 2018 the Company made an early repayment of the remaining balance of a loan originally scheduled to be fully repaid by July 2019 in the amount of \$ 2,237. The impact of the early repayment on the financial statement was immaterial

Information For Investors

Capital structure

The issued share capital is divided into 10,496,761 registered shares with a par value of NIS 0.01 each (excluding 381,730 ordinary shares of NIS 0.01 par value each held by SHL)

Significant shareholders'

As of June 30, 2018, SHL was aware of the following shareholders with more than 3% of all voting rights in the company.

	Number of Ordinary Shares Held	% Including Treasury Shares	% Excluding Treasury Shares
Cai Mengke	3,247,075	29.85%	30.93%
Shen Kun	2,722,338	25.02%	25.94%
Alroy Group	2,507,608	23.05%	23.89%
G.Z. Assets and Management Ltd.	921,533	8.47%	8.78%
Himalaya Asset Management Limited	8,350	0.08%	0.08%
SHL Treasury shares	381,730	3.51%	-

The above table of Significant Shareholders reflects both actual holdings as of June 30, 2018, after deducting from the total number of shares outstanding 381,730 Ordinary Shares held by SHL, and actual holding as of June 30, 2018 calculated including ordinary shares held by SHL, all as indicated above, but does not reflect holding on a fully diluted basis. All in accordance with notifications received by the Company from shareholders and the SAG registrar as of June 30, 2018.

Statistics on SHL Telemedicine as at June 30, 2018

Registered shares with a par value of NIS 0.01 each	
Securities number	1128957
Number of shares*	10,496,731
Market price high/low (CHF)	8.02/6.00
Market capitalization high/low (CHF million)	84.2/63.0
Market capitalization 30/06/18 (CHF million)	79.4
Share capital – nominal value (NIS)	104,967

*Excluding 381,730 ordinary shares held by SHL.

Share price development



Listing

All SHL shares are listed on SIX Swiss Exchange

Ticker symbol: SHLTN

Currency: CHF

Listing date: November 15, 2000

Investor relations

SHL Telemedicine Ltd.

Yoav Rubinstein, CEO

Email: yoavr@shl-telemedicine.com

Yossi Vadnagra, Chief Financial Officer

Email: yossiv@shl-telemedicine.com

90 Igal Alon St., Tel Aviv 67891, Israel

Tel. ++972 3 561 2212

Fax: ++972 3 624 2414